Gerresheimer Shares Plunge Amid Deepening Accounting Crisis

German packaging firm Gerresheimer faces a historic stock selloff and widened BaFin probe over accounting errors, forcing a profit warning and strategic asset sale.

The German packaging specialist Gerresheimer finds itself in a storm of financial uncertainty. With regulators intensifying their scrutiny and investors fleeing, the company's failure to publish its annual report is just the tip of the iceberg. Market participants and shareholder advocates are now grappling with a fundamental concern: what is the true extent of the financial discrepancies?

Market Confidence Evaporates, Triggering Historic Selloff

The reaction on the stock market has been severe. The company's shares recently closed at €16.80, a price level not seen since the depths of the 2009 financial crisis. This represents a staggering year-to-date decline of 39.39%. From its 52-week high of €82.00, the stock has plummeted nearly 80%, indicating a near-total erosion of investor trust. This selloff is directly tied to the dual pressures of regulatory investigations and the absence of audited financial statements.

Regulatory Scrutiny Expands Significantly

The situation escalated dramatically on February 25, when the SDax-listed group disclosed that Germany's financial regulator, BaFin, has widened its probe. Authorities are not only conducting an intensive review of the 2024 consolidated financial statements but have also launched a separate, parallel investigation into the 2025 half-year financial report.

The list of alleged deficiencies is substantial. BaFin has raised concerns over potentially misstated lease liabilities, omitted impairment charges, and a possibly outdated risk reporting system. A particularly critical area under examination is revenue recognition. The regulator has identified "concrete evidence" of errors in the 2023/24 accounts, specifically focusing on "bill-and-hold" transactions where revenue was booked before goods had physically left the company. Internal reviews have already confirmed that employees violated accounting rules, leading to a necessary correction of €35 million in revenue for 2024 alone.

Operational Fallout and Strategic Asset Sales

The accounting turmoil is having a direct and negative impact on the company's operational outlook. For the 2025 fiscal year, management has been forced to downgrade its forecast, now anticipating a decline in revenue and an adjusted EBITDA margin of only 16.5% to 17.5%. Furthermore, the results are being burdened by impairment charges of up to €240 million, primarily stemming from issues at subsidiary operations in Switzerland and the United States.

In a bid to stabilize its financial position, the leadership is taking drastic measures. The company plans to sell its U.S. subsidiary, Centor—a profitable manufacturer of pharmaceutical packaging—within the current 2026 calendar year. While this move would generate urgently needed liquidity, it also means divesting a key contributor to earnings.

A Landscape Dominated by Uncertainty

The outlook for shareholders remains fraught with risk. As long as the twin BaFin investigations are ongoing and no certified annual financial statement is available, there is no reliable basis for a sound valuation of the company. Legal troubles are also mounting, with the shareholder association DSW already examining potential claims for damages. The next scheduled milestone is April 16, 2026, the intended publication date for the first-quarter report, assuming no further delays occur. Until then, the cloud of uncertainty shows no sign of lifting.